Ketoconazole decreases the clearance of reboxetine, without apparently altering its adverse effect profile. Other
azoles are predicted to interact similarly.
It has been suggested that caution should be used, and a reduction in
reboxetine dosage considered, if it is given with
ketoconazole. The manufacturers recommend that
azoles should not be given with
reboxetine as it has a narrow therapeutic index, but this seems overly cautious.